Base de dados : LILACS
Pesquisa : D03.066.515.475 [Categoria DeCS]
Referências encontradas : 56 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 56 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-762679
Autor: Figueroa, Catalina; Droppelmann, Katherine; Quiñones, Verónica; Amigo, Ludwig; Mendoza, Camila; Serrano, Valentina; Véjar, Margarita; Maiz, Alberto; Rigotti, Attilio.
Título: El ácido nicotínico aumenta el transporte celular de colesterol de las lipoproteínas de alta densidad en pacientes con hipoalfalipoproteinemia / Nicotinic acid increases cellular transport of high density lipoprotein cholesterol in patients with hypoalphalipoproteinemia
Fonte: Rev. méd. Chile;143(9):1097-1104, set. 2015. ilus, tab.
Idioma: es.
Projeto: FONDECYT; . Merck S.A. Chile; . Universidad Católica de Chile. Dirección de Investigación, Escuela de Medicina.
Resumo: Background: Plasma high density lipoproteins (HDL) are involved in reverse cholesterol transport mediated by the scavenger receptor class B type I (SR-BI). Nicotinic acid increases HDL cholesterol levels, even though its specific impact on SR-BI dependent-cellular cholesterol transport remains unknown. Aim: To determine the effect of nicotinic acid on HDL particle functionality in cholesterol efflux and uptake mediated by SR-BI in cultured cells in hypoalphalipoproteinemic patients. Material and Methods: In a pilot study, eight patients with low HDL (≤ 40 mg/dL) were treated with extended release nicotinic acid. HDL cholesterol and phospholipid levels, HDL2 and HDL3 fractions and HDL particle sizes were measured at baseline and post-therapy. Before and after nicotinic acid treatment, HDL particles were used for cholesterol transport studies in cells transfected with SR-BI. Results: Nicotinic acid treatment raised total HDL cholesterol and phospholipids, HDL2 levels as well as HDL particle size. Nicotinic acid significantly increased HDL cholesterol efflux and uptake capacity mediated by SR-BI in cultured cells. Conclusions: Nicotinic acid therapy increases SR-BI-dependent HDL cholesterol transport in cultured cells, establishing a new cellular mechanism by which this lipid-lowering drug appears to modulate HDL metabolism in patients with hypoalphalipoproteinemia.
Descritores: HDL-Colesterol/metabolismo
Hipoalfalipoproteinemias/metabolismo
Hipolipemiantes/farmacologia
Lipoproteínas HDL/metabolismo
Niacina/farmacologia
-Transporte Biológico
HDL-Colesterol/efeitos dos fármacos
Projetos Piloto
Fosfolipídeos/sangue
Receptores Depuradores Classe B/metabolismo
Limites: Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: CL1.1 - Biblioteca Central


  2 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Venezuela
Texto completo
Id: lil-749956
Autor: Carias, Diamela; García-Casal, María Nieves; Soto de Sanabria, Ingrid; López Rodríguez, Ana Victoria.
Título: Valores de referencia de niacina para la población venezolana / Reference values of niacin for the Venezuelan population
Fonte: Arch. latinoam. nutr;63(4):329-337, dic. 2013. tab.
Idioma: es.
Resumo: La niacina es una vitamina hidrosoluble, conocida también como ácido nicotínico o vitamina B3. La nicotinamida es un derivado de la niacina (amida del ácido nicotínico), y es utilizada por el cuerpo para producir las coenzimas nicotinamida adenina dinucleótido (NAD) y nicotinamida adenina dinucleótido fosfato (NADP). En esta revisión de los requerimientos de niacina para Venezuela, encontramos que los datos nacionales no son suficientes para establecer las recomendaciones de consumo de este nutriente, por lo tanto, al igual que en la revisión del año 2000, las recomendaciones actuales se basan en las definidas para la población de Estados Unidos. Las Ingestas Dietéticas Recomendadas (RDAs) para Venezuela son: menores de 1 año (2-4 mg/día), niños entre 1 y 8 años (6-8 mg/día), niños entre 9 y 13 años (12 mg/día), adolescentes y adultos del sexo femenino (14 mg/día), adolescentes y adultos del sexo masculino (16 mg/día), embarazadas (18 mg/día) y lactancia (17 mg/ día). En cuanto al Requerimiento Promedio Estimado (EAR): 5-9 mg/día para niños, 11 mg/día para adolescentes y adultos del sexo femenino y 12 mg/día para adolescentes y adultos del sexo masculino, aumentado a 14 mg/día para embarazadas y a 13 mg/ día durante la lactancia. Los Niveles de Ingesta Máximos Tolerables (UL) son: niños entre 1 y 3 años (10 mg/día), niños entre 4 y 8 años (15 mg/día), niños entre 9 y 13 años (20 mg/día), adolescentes (30 mg/día) y adultos (35 mg/día). Es necesario realizar estudios donde se evalúe el estado nutricional de esta vitamina en diferentes grupos de la población, que incluya no solo la estimación del consumo, sino la utilización de indicadores bioquímicos, como la medición de los niveles de las coenzimas NAD y NADP en eritrocitos o sangre completa y la determinación de los principales metabolitos urinarios de la vitamina.

Niacin is a water soluble vitamin, also known as nicotinic acid or Vitamin B3. Nicotinamide is a derivative of niacin (amide of nicotinic acid), and is used by the body to produce the coenzyme nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). In preparing this review about the niacin requirements for Venezuela, it was found that there is not enough national data to establish recommendations, therefore, as in the 2000 review of the Venezuelan Recommended Dietary Allowances (RDAs), the actual recommendations for intake of niacin, are based on those reported for the United States population. The RDAs for Venezuela are: 2-4 mg/day for infants less than 1 year old, 6-8 mg/ day for children between 1 and 8 years, 12 mg/day for children between 9 and 13 years, 14 mg/day for adolescents and female adults, 16 mg/day for adolescents and adult males, 18 mg/day during pregnancy and 17 mg/day during lactation. The estimated average requirement (EAR) is: 6-9 mg/day for children, 11 mg/ day for adolescents and female adults and 12 mg/day for adolescents and adult males, increasing to 14 mg/day during pregnancy and to 13 mg/day during lactation. The niacin Tolerable Upper Intake Levels (UL) are: 10 mg/day for children between 1 and 3 years, 15 mg/day for children between 4 and 8 years, 20 mg/day for children between 9 and 13 years, 30 mg/day for adolescents and 35 mg/day for adults. It is necessary to perform studies where the nutritional status of this vitamin is evaluated for different population groups, including not only the estimation of consumption, but the use of biochemical indicators, such as measuring the levels of the coenzymes NAD and NADP in erythrocytes or whole blood and determination of the major urinary metabolites of the vitamin.
Descritores: Niacina/administração & dosagem
Recomendações Nutricionais
Complexo Vitamínico B/administração & dosagem
-Valores de Referência
Venezuela
Limites: Adolescente
Adulto
Idoso
Criança
Pré-Escolar
Feminino
Seres Humanos
Lactente
Recém-Nascido
Masculino
Meia-Idade
Gravidez
Adulto Jovem
Tipo de Publ: Revisão
Responsável: VE1.1 - Biblioteca Humberto Garcia Arocha


  3 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-741067
Autor: Tavares, Glaysson Tassara; Chiacchio, Nilton Gioia Di; Chiacchio, Nilton Di; Souza, Marcos Vilela de.
Título: Onychomatricoma: a tumor unknown to dermatologists
Fonte: An. bras. dermatol;90(2):265-267, Mar-Apr/2015. graf.
Idioma: en.
Resumo: A sixty-one year old white female was referred to the Dermatology Department to treat an ingrown nail in the inner corner of the left hallux. Examination of the entire nail unit showed the presence of xanthonychia in the outer corner besides thickening and increase in the transverse curvature of the nail plate. Dermoscopy and nuclear magnetic resonance of the free edge of the nail plate detected characteristic signs of onychomatricoma, a diagnosis that was later confirmed by anatomopathological exam.
Descritores: Anticolesterolemiantes/uso terapêutico
Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores
Ácidos Fíbricos/uso terapêutico
Lipoproteínas HDL/sangue
Niacina/uso terapêutico
-Doença das Coronárias/sangue
Doença das Coronárias/mortalidade
Doença das Coronárias/prevenção & controle
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Infarto do Miocárdio/sangue
Infarto do Miocárdio/mortalidade
Infarto do Miocárdio/prevenção & controle
Oxazolidinonas/uso terapêutico
Quinolinas/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Acidente Vascular Cerebral/sangue
Acidente Vascular Cerebral/mortalidade
Acidente Vascular Cerebral/prevenção & controle
Compostos de Sulfidrila/uso terapêutico
Limites: Seres Humanos
Tipo de Publ: Metanálise
Revisão
Responsável: BR1.1 - BIREME


  4 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-684768
Autor: Palhares, Daniel Moore Freitas; Albuquerque, Nikole Nascimento de; Foureaux, Fernanda de Souza; Pereira, Fabiana Resende; Alkmin, Maria Beatriz Moreira; Leite, Jacqueline Alvarez.
Título: Caso 6 / Case 6
Fonte: Rev. méd. Minas Gerais;22(2), jun. 2012.
Idioma: pt.
Resumo: Mulher, 54 anos, procurou atenção básica em município de Minas Gerais com queixa de lesões descamativas e pruriginosas em área de exposição solar, há cerca de 2 meses. Essa é a segunda vez que manifesta estes sinais e não sabe precisar há quanto tempo ocorreu o primeiro episódio. Relata que no intervalo entre eles não apresentou qualquer tipo de lesão cutânea. A paciente é alcoolista, tabagista, hipertensa e não faz uso de medicamentos.
Descritores: Pelagra/diagnóstico
Pelagra/etiologia
Pelagra/terapia
-Diagnóstico Diferencial
Niacina/uso terapêutico
Limites: Seres Humanos
Responsável: BR21.1 - Biblioteca J Baeta Vianna- Campus Saúde UFMG


  5 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Id: lil-669873
Autor: Kowalski, Robert E.
Título: A cura do colesterol em 8 semanas / The cure cholesterol after 8 weeks.
Fonte: São Paulo; Cultura; 1989. 350 p. tab.
Idioma: pt.
Descritores: Colesterol
Niacina
Limites: Seres Humanos
Responsável: BR75.1 - Biblioteca
BR75.1; 616.12, K849c. 1436


  6 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-655388
Autor: Lameiro, Magna da Glória; Helbig, Elizabete; Zavareze, Elessandra da Rosa; Moura, Fernanda Aline de; Tavares, Rafael Aldrighi; Vargas, Carolina Galarza; Borges, Lúcia Rota; Elias, Moacir Cardoso; Dias, Alvaro Renato Guerra.
Título: Lipid profiles of rats fed with diets supplemented with vitamins niacin and pyridoxine
Fonte: Rev. ciênc. farm. básica apl;33(2), ago. 2012.
Idioma: en.
Resumo: Hypercholesterolemia is a major risk factor for cardiovascular disease. Supplements containing the vitamins niacin (B3) and pyridoxine (B6) can promote the reduction of total cholesterol and an increase in HDL cholesterol. In this study, the effects of diets supplemented with niacin (B3) and pyridoxine (B6) on the hepatic and serum lipid profiles of Wistar rats were assessed. The diets were prepared with combinations of three concentrations of niacin (3, 4 and 5 g/kg) and pyridoxine (6, 12 and 18 mg/kg) and one with neither vitamin. The animals were divided into eleven experimental groups of six animals per group, and nine groups were fed on a standard diet with 7.5% fat and vitamin supplementation. Another group was fed with 7.5% fat without vitamin supplements. A control group received the standard diet (AIN-93M) without modifications (4% fat). The weight gain, food intake, serum and hepatic total cholesterol, serum cholesterol fractions (HDL, LDL, and VLDL), serum and hepatic triacylglycerols and hepatic and fecal lipid contents were measured after 30 days. The diet with the highest concentration of niacin and lowest concentration of pyridoxine had the lowest level of total hepatic cholesterol. Hepatic triacylglycerols were reduced by the highest concentration of niacin (5 g/kg), and this reduction was enhanced by increasing the pyridoxine concentration. The diets supplemented with niacin and pyridoxine reduced the levels of serum total cholesterol, LDL, VLDL, triacylglycerols and hepatic lipids. These effects on the lipid profile varied with the concentrations of the two vitamins and the interactions between them.
Descritores: Colesterol
HDL-Colesterol
Niacina/uso terapêutico
Piridoxina/uso terapêutico
Ratos Wistar
Limites: Animais
Ratos
Responsável: BR33.1 - Divisão Técnica de Biblioteca e Documentação


  7 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Costa Rica
Texto completo
Id: lil-580248
Autor: Martínez Ortiz, J. A; Páez L., von Saalfeld K.
Título: Tratamiento de dislipidemias con ácido nicotínico / Treatment of dyslipidemia with Nicotinic acid
Fonte: Rev. costarric. cardiol;4(1):23-27, ene.-abr. 2002. ilus.
Idioma: es.
Resumo: El ácido nicotínico fue el primer agente para el tratamiento de dislipidemias. Con la aparición de las estatinas su uso disminuyó ya que éstas no presentaban los efectos molestos de ruborizacioón causados por el ácido nicotínico. Las estatinas no han demostrado ser tan efectivas para la reducción de los triglicéridos y en el aumento de las lipoproteínas de alta densidad como el ácido nicotínico. Se han desarrollado dos variaciones adicionales de ácido nicotínco con el objetivo de disminuir su poder de causar ruborización y de suministrar un mejor efecto de regulación sobre esos lípidos. En el presente artículo se realiza una revisión de la literatura médica sobre el uso del ácido nicotínico como agente para el control de las dislipidemias. Las dislipidemias son un grupo de trastornos caracterizados por anomalías tanto cuantitativas como cualitativas de las lipoproteínas plasmáticas. La excesiva aucumulación de una se acompaña generalmente de una disminución en la concentración de la otra. Se pueden considerar como el resultado de defectos en el sistema catabólico por anomalías en las enzimas, receptores celulares de superficie, o bien de una estructura anormal de la partícula lipoprotéica que disminuye su capacidad para interactuar con los mecanismo catabólicos. La mayoría de las dislipidemias son poligénicas o el producto de la interacción entre factores ambientales y cierta predisposición genética.
Descritores: Hiperlipidemias/tratamento farmacológico
Hiperlipidemias/terapia
Niacina
Limites: Seres Humanos
Responsável: CR1.1 - BINASSS - Biblioteca Nacional de Salud y Seguridad Social


  8 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-565426
Autor: Urquiaga Calderón, Juan.
Título: Perspectivas del HDL colesterol, como objetivo en el llamado riesgo cardiovascular residual / Prospects of HDL cholesterol, the so-called objective residual cardiovascular risk
Fonte: Rev. peru. cardiol. (Lima);36(1):44-49, ene.-abr. 2010. tab.
Idioma: es.
Descritores: Aterosclerose
HDL-Colesterol/classificação
HDL-Colesterol
Niacina
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: PE1.1 - Oficina Universitária de Biblioteca


  9 / 56 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-548862
Autor: Ruiz, Álvaro J.
Título: Dislipidemias y riesgo cardiovascular: ¿Tiempo para un nuevo enfoque en lípidos? / Dyslipidemias and cardiovascular risk: time for a new appoach to lipid disorders?
Fonte: Rev. colomb. cardiol;16(5):214-220, sept.-oct. 2009.
Idioma: es.
Resumo: La enfermedad coronaria es una entidad con causas múltiples, la primera causa de mortalidad en el mundo actual y, para el año 2025, la primera causa de morbilidad mundial. Dado su origen multicausal, el enfoque debe ser también múltiple; con revisión a todos los factores. Uno de los factores de riesgo, la dislipidemia, tiene varios aspectos que necesitan atención y control, aunque ésta se haya centrado tradicionalmente en el c-LDL, sin prestar mayor cuidado a las otras subfracciones. Los estudios clásicos en lípidos, principalmente con estatinas, han dirigido su atención, al c-LDL y se encuentran estudios en los que hay reducción en c-LDL sin cambios (o con muy pocos) en c-HDL. Aunque hay disminución en el riesgo de eventos y mortalidad, pueden apreciarse riesgos residuales significativos. Un estudio con fibratos tuvo los resultados opuestos, un aumento significativo en el c-HDL sin cambio en el c-LDL, y se observó una reducción interesante en el riesgo, pero con un riesgo similar al observado en los estudios con estatinas. Los estudios con intervenciones múltiples que impactan todas las subfracciones lipídicas, han mostrado cambios significativamente mejores en riesgo. La adición de niacina de liberación extendida al armamentario terapéutico ha permitido, en combinación con estatinas, obtener un mejor control de todas las subfracciones lipídicas, así como reducciones significativas en riesgo y en crecimiento de placa. Los efectos de la niacida de liberación extendida son reducción de c-LDL y triglicéridos, aumento en c-HDL y también reducción en LP(a), así como cambios benéficos en apoA y apoB. Las reacciones adversas, como el enrojecimiento, pueden controlarse y en muchos casos evitarse, y han mostrado ser pasajeras y disminuir hasta desaparecer con el tiempo.

Coronary artery disease is an entity with multiple causes. It is the first cause of mortality in the world, and for the year 2025, will be the first cause of morbidity. Given its multi-causal origin, the approach must also be multiple and all factors should be controlled. Dyslipidemia, one of the main risk factors, has several aspects that need attention and control, although the attention has traditionally been focused on LDL-c, disregarding other lipidic subfractions. Classical lipid studies mainly those with statins, have directed their attention to LDL-c, and there are studies in which there is a LDL-c reduction without little or no change in HDL-C. Even though events and mortality risks decrease, significant residual risks can be appreciated. A study with fibrates had the opposite results, showing significant increase in HDL-c without any change in LDL-c, and an interesting decrease in risk but also with a similar risk to that found in previous studies with statins was observed. Studies with multiple interventions that impact all lipidic sub-fractions have shown better significant changes in risk. Addition of niacin extended release to the pool of drugs in combination witn statins, has allowed to achieve a better control of all the lipidic subfractions as well as significant reductions in risk and plaque growth. The effects of the niacin extended release are reduction of LDL-c and triglycerides, increase in HDL-c and also LP(a) reduction, as well as beneficial changes in ApoA and ApoB. Adverse reactions, such as flushing, can be controlled and in many cases avoided, and have shown to be transient and to decrease and even disappear with time.
Descritores: HDL-Colesterol
Dislipidemias
Niacina
Tipo de Publ: Relatos de Casos
Responsável: CO369.9 - SCC - Sociedad Colombiana de Cardiologia y Cirugía Cardiovascular


  10 / 56 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
ALMEIDA-MURADIAN, LIGIA BICUDO DE
Texto completo
Id: lil-544604
Autor: Moreschi, Elaine Cristina Pinto; Almeida-Muradian, Ligia Bicudo de.
Título: Vitamins B1, B2, B6 and PP contents in royal jelly
Fonte: Rev. Inst. Adolfo Lutz;68(2):187-191, maio-ago. 2009. tab.
Idioma: en.
Resumo: Hydrosoluble vitamins B1, B2, B6 and PP are essential organic substances for human organism, functioning as coenzymes on several metabolic cycles. In the present investigation four vitamins of B complex and its vitamers contents were determined in royal jelly samples marketed in São Paulo, Brazil. A single extraction process was employed, and each vitamin was determined by HPLC using C18 column and detected by fluorescence. Four samples from different suppliers were analyzed, and the results varied from 0.08 to 0.41 mg/100g (vitamin B1 orthiamine); from 0.01 to 0.05 mg/100g (vitamin B2 or ribofl avin); from 0.13 to 0.38 mg/100g (piridoxal - vitamin B6); from 0.26 to 1.38 mg/100g (piridoxamine - vitamin B6); from 0.21 to 0.57 mg/100g (niacin - vitamin PP);and from 1.56 to 2.00 mg/100g (niacinamide - vitamin PP). These data show that royal jelly is not an important source of the analyzed vitamins, though the results indicate that the employed technique is suitable for determining these four vitamins and its vitamers.
Descritores: Abelhas
Niacina
Riboflavina
Tiamina
Vitaminas
Responsável: BR91.2 - Centro de Documentação



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde